Bullish & Foolish
Full ATRA fundamentals All 466 on the Survival Watch

ATRAATARA BIOTHERAPEUTICS, INC.

Is Atara Biotherapeutics struggling financially?

Yes, by its own account. Atara Biotherapeutics told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Regulatory win

    We continue to advance development of tab-cel in the U.S. in a Phase 3 clinical trial for patients with EBV+ PTLD (ALLELE).

    Form 10-Q, filed 12 May 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$97.4M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$9.9M

÷

Cash burned over the last 12 months

$60.4M

What Atara Biotherapeutics told the SEC

…operations for at least 12 months from the date of issuance of these condensed consolidated financial statements. To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, we plan to secure additional capital, potentially through a combination of public or private security offerings; use of our ATM facility as described in Note 10; issuance of debt;…

ATARA BIOTHERAPEUTICS, INC., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 26.8% share-count increase The company issued stock. Each share now owns 21.1% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 54% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt